Open4.460 | Close4.480 |
Vol / Avg.13.248K / 15.641K | Mkt Cap42.552M |
Day Range4.460 - 4.500 | 52 Wk Range4.260 - 7.840 |
ImmuCell Stock (NASDAQ: ICCC) stock price, news, charts, stock research, profile.
Open4.460 | Close4.480 |
Vol / Avg.13.248K / 15.641K | Mkt Cap42.552M |
Day Range4.460 - 4.500 | 52 Wk Range4.260 - 7.840 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | ||||||
REV | 5.397M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2020-07-13 | Aegis Capital | Nathan Weinstein | Initiates Coverage On | Buy | Announces | - | 14.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ICCC | ImmuCell | 20.93% | 42.6M |
OCX | OncoCyte | 0% | 31.4M |
GANX | Gain Therapeutics | 0.47% | 34.1M |
INTS | Intensity Therapeutics | 30.18% | 43.7M |
COEP | Coeptis Therapeutics | 1.71% | 40.6M |
You can purchase shares of ImmuCell (NASDAQ: ICCC) through any online brokerage.
Other companies in ImmuCell’s space includes: OncoCyte (NASDAQ:OCX), Gain Therapeutics (NASDAQ:GANX), Intensity Therapeutics (NASDAQ:INTS), Coeptis Therapeutics (NASDAQ:COEP) and Bolt Biotherapeutics (NASDAQ:BOLT).
The latest price target for ImmuCell (NASDAQ: ICCC) was reported by Aegis Capital on Monday, July 13, 2020. The analyst firm set a price target for 14.00 expecting ICCC to rise to within 12 months (a possible 155.01% upside). 0 analyst firms have reported ratings in the last year.
The stock price for ImmuCell (NASDAQ: ICCC) is $5.49 last updated November 8, 2023 at 2:29 PM UTC.
There is no dividend information for ImmuCell.
ImmuCell’s Q4 earnings are confirmed for Tuesday, February 20, 2024.
There is no upcoming split for ImmuCell.
ImmuCell is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.